Globe Newswire

NEW YORK, May 18, 2024 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Sprout Social, Inc. (NASDAQ: SPT) between November 2, 2023 and May 2, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 12, 2024.

SO WHAT: If you... (continue reading...)

NEW YORK, May 18, 2024 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of CI&T Inc (NYSE: CINT) resulting from allegations that CI&T may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased CI&T securities you may be entitled to compensation without payment of any out of pocket fees or costs through a... (continue reading...)

SINGAPORE, May 18, 2024 (GLOBE NEWSWIRE) -- OKX, a leading Web3 technology company, has issued updates for May 18, 2024.

OKX Wallet Announces Integration with Runes Bridge

OKX Wallet is now integrated with Runes Bridge. This integration provides users with a robust and fortified bridge mechanism for seamlessly transferring assets based on the Runes standard from Bitcoin to other networks including Ethereum, Arbitrum, BNB Chain, Polygon, and vice versa.

To access... (continue reading...)

NEW YORK, May 18, 2024 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of The Chemours Company (NYSE: CC) between February 10, 2023 and February 28, 2024, both dates inclusive (the “Class Period”), of the important May 20, 2024 lead plaintiff deadline.

SO WHAT: If you purchased Chemours common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees... (continue reading...)

Results from a Phase 2 study show combination of OCA 5-10mg and bezafibrate 400mg induced the greatest percent change from baseline in ALP at Month 6

OCA and bezafibrate combination therapy has acceptable metabolic profile

Results featured in podium presentation today at DDW 2024

MORRISTOWN, N.J., May 18, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused... (continue reading...)